Claims
- 1. A substantially pure polypeptide, wherein said polypeptide comprises the amino acid sequence of GluR1 (Sequence ID No. 2), GluR2 (Sequence ID No. 4), GluR3 (Sequence ID No. 6), GluR4 (Sequence ID No. 8), GluR5 (Sequence ID No. 10), GluR6 (Sequence ID No. 12), or GluR7 (Sequence ID No. 14), and immunologically reactive fragments thereof.
- 2. A polypeptide according to claim 1, said immunologically reactive fragements comprising at least 15 contiguous amino acids of GluR1 (Sequence ID No. 2), GluR2 (Sequence ID No. 4), GluR3 (Sequence ID No. 6), GluR4 (Sequence ID No. 8), GluR5 (Sequence ID No. 10), GluR6 (Sequence ID No. 12), or GluR7 (Sequence ID No. 14).
- 3. A composition comprising a recombinant homomeric receptor formed of any one of the polypeptides GluR1 (Sequence ID No. 2), GluR2 (Sequence ID No. 4), GluR3 (Sequence ID No. 6), GluR4 (Sequence ID No. 8), GluR5 (Sequence ID No. 10), GluR6 (Sequence ID No. 12), or GluR7 (Sequence ID No, 14).
- 4. A composition comprising a recombinant heteromeric receptor formed of any two or more of the polypeptides GluR1 (Sequence ID No. 2), GluR2 (Sequence ID No. 4), GluR3 (Sequence ID No. 6), GluR4 (Sequence ID No. 8), GluR5 (Sequence ID No. 10), GluR6 (Sequence ID No. 12), or GluR7 (Sequence ID No. 14).
- 5. A substantially pure mammalian polypeptide, wherein said polypeptide is encoded by a cDNA which hybridizes under low stringency conditions to the complement of a nucleic acid having a nucleotide sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11 and SEQ ID NO: 13.
- 6. A substantially pure mammalian polypeptide according to claim 5 wherein said nucleotide sequence is SEQ ID NO:1.
- 7. A substantially pure mammalian polypeptide according to claim 5 wherein said nucleotide sequence is SEQ ID NO:3.
- 8. A substantially pure mammalian polypeptide according to claim 5 wherein said nucleotide sequence is SEQ ID NO:5.
- 9. A substantially pure mammalian polypeptide according to claim 5 wherein said nucleotide sequence is SEQ ID NO:7.
- 10. A substantially pure mammalian polypeptide according to claim 5 wherein said nucleotide sequence is SEQ ID NO:9.
- 11. A substantially pure mammalian polypeptide according to claim 5 wherein said nucleotide sequence is SEQ ID NO:11.
- 12. A substantially pure mammalian polypeptide according to claim 5 wherein said nucleotide sequence is SEQ ID NO:13.
PRIOR APPLICATIONS
This application is a divisional application of U.S. Ser. No. 08/013,767, filed Feb. 4, 1993, now abandoned which is a divisional of U.S. Ser. No. 07/718,575, filed Jun. 21, 1991, now U.S. Pat. No. 5,202,257, which is a continuation of PCT Application No. US90/06153, filed Oct. 25, 1990, which is a continuation-in-part application of U.S. Ser. No. 07/428,116, filed October 27, 1989, now abandoned.
ACKNOWLEDGEMENT
This invention was made with Government support under Grant Numbers NS 11549 and NS 28709.01, awarded by the National Institutes of Health. The Government has certain rights in this invention.
Non-Patent Literature Citations (3)
Entry |
Grenningloh et al. Alpha subunit variants of the human glycine receptor: primary structures, functional expression an chromosomal localization of the corresponding genes. The EMBO Journal 9(3):771-776, Mar. 1990. |
Schofield et al. Sequence and expression of human GABA-A receptor alpha1 and beta1 subunits. FEBS Letters 244(2):361-364, FEB. 1989. |
Huetther et al. P.N.A.S. 85:1307-1311, Feb. 1988. |
Divisions (2)
|
Number |
Date |
Country |
Parent |
013767 |
Feb 1993 |
|
Parent |
718575 |
|
|